Outpatient management of Post-COVID syndrome - single center experience

Background: COVID patients continue to experience unremitting symptoms that extend far beyond the initial illness. While there is rapid accumulation of data on acute COVID treatment in hospitalized patients, little is known regarding post-COVID management. Objectives: To describe our center 's experience treating post-COVID sub -syndromes encountered in Post-COVID Lung Clinic. Methods: We retrospectively reviewed data on 98 post-COVID patients evaluated in our clinic between 07/01/ 2020 -12/31/2022. We encountered three distinct post-COVID subtypes: 1) respiratory complaints associated with increased O2 requirements and abnormal CT findings (post-COVID interstitial lung disease [ILD]), 2) respiratory complaints associated with tachycardia (post-COVID dyspnea-tachycardia syndrome [DTS]). PostCOVID ILD patients ( n = 28) received steroids in combination with cell cycle inhibitor (mycophenolate mofetil-MMF). Post-COVID DTS patients ( n = 16) were treated with metoprolol. 3) A third, undifferentiated group presented with mild respiratory complaints and normal spirometry ( n = 17) and was followed in clinic without initiation of a specific treatment. Results: In treated post-COVID ILD patients, mean oxygen requirements at rest (1.96 +/- 1.79 L/NC) decreased to 0.89 +/- 1.29 L/NC at 6 months follow-up, p = 0.005. In patients with post-COVID DTS, mean heart rate at rest decreased (98 +/- 15 bpm to 79 +/- 11 bpm) at 6 months follow-up, p = 0.023. 60 % of patients reported an improvement in exertional dyspnea. Conclusions: Our descriptive study presents a single center outpatient COVID-19 clinic experience. We encountered 3 post-COVID sub -syndromes and describe their treatments: post-COVID interstitial lung disease [ILD] treated with a novel regimen of MMF and steroids, post COVID dyspnea-tachycardia syndrome [DTS] treated with metoprolol, and a third subgroup with mild undifferentiated symptoms without specific treatment.